UK's NICE calls for more data to consider Roche drug for a type of vasculitis The Pharma Letter UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published draft guidance on Swiss drug major Roche's (ROG: SOX) blockbuster cancer drug MabThera (rituximab), which is also licensed for inducing ... NICE demands more data from Roche for MabThera in rare autoimmune disease |
